Photo from archive.org
Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether… Click to show full abstract
Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona's investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical trials.
Keywords:
buys tizona;
gilead;
gilead buys;
hla strategy;
tizona anti;
anti hla
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!